Alnylam Pharmaceuticals, Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Alnylam Pharmaceuticals, Inc. |
| Ticker: | Ticker: ALNY |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.
On this news, shares of Alnylam fell $81.14 per share, or approximately 28%, to close at on $205.48 per share July 30, 2026.
On this news, shares of Alnylam fell $81.14 per share, or approximately 28%, to close at on $205.48 per share July 30, 2026.